enGene (NASDAQ:ENGN) Receives Buy Rating from HC Wainwright

by · The Cerbat Gem

HC Wainwright reissued their buy rating on shares of enGene (NASDAQ:ENGN – Free Report) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock. HC Wainwright also issued estimates for enGene’s Q2 2025 earnings at ($0.60) EPS, Q3 2025 earnings at ($0.63) EPS, Q4 2025 earnings at ($0.65) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.96) EPS and FY2029 earnings at ($0.15) EPS.

A number of other research analysts also recently issued reports on the stock. UBS Group downgraded shares of enGene from a “buy” rating to a “neutral” rating and dropped their target price for the company from $34.00 to $7.00 in a research report on Friday, February 14th. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a report on Monday, November 18th. Piper Sandler assumed coverage on enGene in a research note on Tuesday, February 18th. They issued an “overweight” rating and a $26.00 target price for the company. Raymond James started coverage on enGene in a research report on Wednesday, November 27th. They issued an “outperform” rating and a $23.00 target price for the company. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 price target on shares of enGene in a report on Monday, December 23rd. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $25.22.

Check Out Our Latest Stock Analysis on enGene

enGene Stock Performance

ENGN stock opened at $5.35 on Tuesday. enGene has a 1-year low of $4.42 and a 1-year high of $18.40. The company has a current ratio of 16.87, a quick ratio of 16.87 and a debt-to-equity ratio of 0.08. The stock has a 50-day moving average price of $6.56 and a 200-day moving average price of $7.12. The firm has a market cap of $272.73 million, a PE ratio of -9.22 and a beta of -0.61.

enGene (NASDAQ:ENGN – Get Free Report) last issued its earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. As a group, equities research analysts expect that enGene will post -1.56 earnings per share for the current year.

Institutional Trading of enGene

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wolverine Asset Management LLC purchased a new position in shares of enGene during the third quarter valued at approximately $37,000. Point72 Asset Management L.P. raised its position in enGene by 1,410.3% in the 3rd quarter. Point72 Asset Management L.P. now owns 663,000 shares of the company’s stock valued at $4,376,000 after buying an additional 619,100 shares during the last quarter. Franklin Resources Inc. lifted its stake in enGene by 48.7% during the 3rd quarter. Franklin Resources Inc. now owns 1,189,952 shares of the company’s stock valued at $7,854,000 after acquiring an additional 389,918 shares in the last quarter. Vontobel Holding Ltd. purchased a new position in enGene during the 4th quarter worth $69,000. Finally, Blue Owl Capital Holdings LP grew its stake in shares of enGene by 3.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 3,159,975 shares of the company’s stock worth $21,014,000 after acquiring an additional 101,006 shares in the last quarter. 64.16% of the stock is owned by institutional investors.

About enGene

(Get Free Report)

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

Further Reading